Want to see GALT full AI Analyst Report?
Top Page
Galectin Therapeutics
(NASDAQ:GALT)
Select Model
Select Model
Rating:49Neutral
Price Target:
$3.00
▼(-13.54% Downside)
Action:Reiterated
Date:08/05/26
The score is held down primarily by weak financial performance (no revenue, persistent losses and cash burn, and a previously very strained capital structure) and bearish technical signals (below key moving averages with negative MACD). Offsetting these risks, recent corporate events are constructive—especially the large debt reduction via conversion and clearer FDA-aligned Phase 3 pathway—supporting a slightly higher, but still cautious, overall rating.
Positive Factors
Regulatory clarity — Phase 3 pathway
Securing FDA agreement on endpoints, trial design and a traditional full‑approval pathway materially reduces regulatory execution risk. This durable clarity increases the probability a single adequate Phase 3 could support approval, improves partnerability and focuses development planning over the next 2–6 months.
Negative Factors
No commercial revenue (clinical-stage)
As a clinical‑stage biopharma with no approved products, the company lacks operating revenue and must fund development externally. This structural absence of commercial cash flow means long‑term program continuity depends on financing or partnerships, increasing execution and dilution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory clarity — Phase 3 pathway
Securing FDA agreement on endpoints, trial design and a traditional full‑approval pathway materially reduces regulatory execution risk. This durable clarity increases the probability a single adequate Phase 3 could support approval, improves partnerability and focuses development planning over the next 2–6 months.
Read all positive factors
Galectin Therapeutics (GALT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$195.59M
Dividend YieldN/A
Average Volume (3M)982.04K
Price to Earnings (P/E)―
Beta (1Y)0.49
Revenue GrowthN/A
EPS Growth43.38%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.41
Shares Outstanding65,856,895
10 Day Avg. Volume678,820
30 Day Avg. Volume982,042
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)-2.11
Price to Sales (P/S)0.00
P/FCF Ratio-11.13
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.00Price Target Upside217.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.37
Revenue Forecast (FY)N/A
Galectin Therapeutics Business Overview & Revenue Model
Company Description
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship...
How the Company Makes Money
Galectin Therapeutics is a clinical-stage biotechnology company and, as such, it generally does not generate recurring revenue from commercial product sales because its lead drug candidate(s) have been in development and not approved for marketing...
Galectin Therapeutics Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
3
Very Negative
Cash Flow
7
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -23.45M | -41.47M | -38.24M | -37.71M | -30.00M |
| Net Income | -30.84M | -47.05M | -41.07M | -38.78M | -30.53M |
Balance Sheet | |||||
| Total Assets | 19.53M | 17.50M | 28.20M | 21.29M | 41.83M |
| Cash, Cash Equivalents and Short-Term Investments | 17.72M | 15.12M | 25.66M | 18.59M | 39.65M |
| Total Debt | 133.76M | 106.25M | 71.81M | 39.87M | 29.06M |
| Total Liabilities | 145.73M | 120.56M | 88.44M | 53.48M | 39.21M |
| Stockholders Equity | -126.19M | -103.07M | -60.24M | -32.19M | 2.62M |
Cash Flow | |||||
| Free Cash Flow | -23.88M | -41.77M | -32.97M | -31.06M | -24.31M |
| Operating Cash Flow | -23.88M | -41.77M | -32.97M | -31.06M | -24.31M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 26.48M | 31.23M | 40.03M | 10.00M | 36.81M |
Galectin Therapeutics Technical Analysis
Positive
3.47
Price Trends
3.48
Negative
2.96
Positive
3.61
Negative
Market Momentum
-0.17
Positive
48.44
Neutral
60.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GALT, the sentiment is Positive. The current price of 3.47 is below the 20-day moving average (MA) of 3.68, below the 50-day MA of 3.48, and below the 200-day MA of 3.61, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 48.44 is Neutral, neither overbought nor oversold. The STOCH value of 60.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GALT.
Galectin Therapeutics Risk Analysis
Galectin Therapeutics disclosed 37 risk factors in its most recent earnings report. Galectin Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Galectin Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $856.92M | 9.11 | -54.39% | ― | ― | ― | |
56 Neutral | $1.20B | -6.76 | -51.34% | ― | ― | 94.97% | |
52 Neutral | $528.90M | -6.28 | -32.33% | ― | ― | 38.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $195.59M | -7.30 | 21.05% | ― | ― | 43.38% | |
48 Neutral | $183.08M | -1.53 | -57.92% | ― | -45.50% | -35.63% | |
46 Neutral | $160.64M | -1.58 | -108.05% | ― | ― | 59.42% |
* Healthcare Sector Average
GALT
Galectin Therapeutics
3.45
-0.70
-16.87%
OMER
Omeros
13.25
9.19
226.35%
VYGR
Voyager Therapeutics
3.27
0.13
4.14%
TECX
Tectonic Therapeutic
30.98
8.67
38.86%
JBIO
Jade Biosciences
21.96
14.47
193.19%
TNYA
Tenaya Therapeutics
0.73
0.06
8.68%
Galectin Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion
Positive
Aug 4, 2026
On July 31, 2026, Galectin Therapeutics converted all outstanding principal and accrued interest under five line-of-credit facilities held by chairman and major shareholder Richard E. Uihlein into equity, issuing 34,376,167 common shares. The move...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Galectin Advances Belapectin to Phase 3 After FDA Alignment
Positive
Jun 23, 2026
On June 23, 2026, Galectin Therapeutics reported positive outcomes from an in‑person Type C meeting with the U.S. Food and Drug Administration, securing agreement on the primary endpoint, trial design and regulatory pathway for Phase 3 devel...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.